Accéder au contenu
Merck

Butalbital-containing agents: should they be banned? No.

Current pain and headache reports (2002-03-02)
Seymour Solomon
RÉSUMÉ

Butalbital compounds are of proven efficacy in the treatment of tension headache. Decades of experience have established their value in the treatment of other mild-to-moderate headaches. Untold numbers of people rely on these medications as their drug of choice or use them when vasoconstrictors, opioids, or nonsteroidal anti-inflammatory agents are contraindicated. The medications are cost-effective with only occasional and minor immediate adverse effects. Their overuse may cause the evolution of episodic primary headaches to chronic daily headaches; however, removal of these agents from the market would reduce the chronic daily headache in the general population by a small fraction of 1%.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Supelco
Butalbital solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®